Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Los Angeles, California

CNS medication trials in Los Angeles, CA

37 CNS medication studies are recruiting participants at sites in Los Angeles as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Los Angeles at a glance

  • 37 studies are recruiting at a site in Los Angeles.
  • By phase: Phase 1/2 (5), Phase 2 (12), Phase 2/3 (1), Phase 3 (15), Phase 4 (4).
  • By sponsor: industry (30), university, hospital or other (7).
  • By research area: Depression (9), Parkinson's Disease (9), Migraine (6), Schizophrenia (6), Epilepsy (4), ADHD (2), Bipolar Disorder (1).
  • Most recent update to one of these records: November 17, 2026.

Depression studies recruiting in Los Angeles

Basic details from each study's public record (the 30 most recently updated of 37). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study sites
    CalNeuro Research Group · Lipov Medical Group
    Registry record
    NCT06793397 · updated
  2. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06966401 · updated
  3. ALTO-207 in Adults With Treatment-resistant Depression (TRD)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT07553637 · updated
  4. ALTO-100 in Bipolar Disorder With Depression (BD-D)

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT06656416 · updated
  5. Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07484217 · updated
  6. NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06963021 · updated
  7. Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Syndeio Biosciences, Inc
    Study site
    CalNeuro Research Group
    Registry record
    NCT06547489 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Schizophrenia studies recruiting in Los Angeles

  1. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    USC - The Memory and Aging Center (MAC) - Alzheimer Disease Research Center (ADRC)
    Registry record
    NCT06585787 · updated
  2. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT07459647 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Los Angeles

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    NRC Research Institute
    Registry record
    NCT06951698 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Los Angeles, CA on ClinicalTrials.gov.

ADHD studies recruiting in Los Angeles

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717892 · updated
  2. AWARE: Management of ADHD in Autism Spectrum Disorder

    • Phase 4
    • Ages 4 to 17
    • All sexes
    Sponsor
    Daniel Coury
    Study site
    Children's Hospital Los Angeles
    Registry record
    NCT05916339 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Los Angeles

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    UCLA Jonsson Comprehensive Cancer Center ( Site 0135) · USC Norris Comprehensive Cancer Center ( Site 0205)
    Registry record
    NCT06623422 · updated
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UCLA Department of Medicine - Hematology & Oncology ( Site 0047)
    Registry record
    NCT06841354 · updated
  3. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UCLA Hematology/Oncology - Santa Monica ( Site 6905)
    Registry record
    NCT06469944 · updated
  4. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study sites
    Keck School of Medicine of USC · UCLA Neurology Outpatient Clinic
    Registry record
    NCT07174310 · updated
  5. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    University of California, Los Angeles
    Registry record
    NCT06680830 · updated
  6. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    • Phase 2
    • Ages 30 to 80
    • All sexes
    Sponsor
    Appello Pharmaceuticals, Inc.
    Study site
    Keck Medicine of USC - USC Healthcare Center 2 (Site #221)
    Registry record
    NCT07432958 · updated
  7. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    • Phase 2/3
    • Ages 40 to 80
    • All sexes
    Sponsor
    Biohaven Therapeutics Ltd.
    Registry record
    NCT06976268 · updated
  8. A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UCLA Hematology/Oncology - Santa Monica ( Site 4905)
    Registry record
    NCT05319730 · updated
  9. Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UCLA Hematology/Oncology - Santa Monica ( Site 8905)
    Registry record
    NCT06445972 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Epilepsy studies recruiting in Los Angeles

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    Brain Science Research Institute
    Registry record
    NCT05667142 · updated
  2. A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    University of California Los Angeles (UCLA)
    Registry record
    NCT05716100 · updated
  3. RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Clinical Research Institute
    Registry record
    NCT06798896 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Migraine studies recruiting in Los Angeles

  1. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Mayo Clinic
    Study sites
    Clinical Research Institute · Keck School of Medicine of USC
    Registry record
    NCT06972056 · updated
  2. Study of EVO756 in Adults With Migraine

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Evommune, Inc.
    Study site
    CA Medical Clinic for Headache
    Registry record
    NCT07616128 · updated
  3. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Clinical Research Institute · Downtown L.A. Research Center, Inc.
    Registry record
    NCT07645924 · updated
  4. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Clinical Research Institute · Downtown L.A. Research Center, Inc.
    Registry record
    NCT07674654 · updated
  5. A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

    • Phase 4
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Clinical Research Institute
    Registry record
    NCT07609914 · updated
  6. A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Clinical Research Institute
    Registry record
    NCT07729462 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Ask about studies near Los Angeles

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call